The Patent Finder

Vegenics Limited

Also on record
Records under this name other than the patents Vegenics Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.

Back to Vegenics Limited

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 9,896,499Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis
Formerly held
In force
 · USPTO record
In forceUSPTO record
US 8,025,886Modified VEGF-A with improved angiogenic properties
Formerly held
In force
 · USPTO record
In forceUSPTO record
US 9,073,997Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis
Formerly held
In force
 · USPTO record
In forceUSPTO record
US 8,940,695Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
Formerly held
Term ended
Term ended Nov 10, 2026 · Medium confidence
Term endedTerm ended Nov 10, 2026Medium confidence
US 7,846,437Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same
Formerly held
Term ended
Term ended Mar 7, 2025 · USPTO record
Term endedTerm ended Mar 7, 2025USPTO record
US 7,307,107Photopolymerizable Composition and Use Thereof
Term ended
Term ended Mar 11, 2024 · High confidence
Term endedTerm ended Mar 11, 2024High confidence
US 7,534,572Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
Formerly held
Lapsed on the fee record
Ended May 19, 2021 · USPTO record
Lapsed on the fee recordEnded May 19, 2021USPTO record
US 6,383,484Antibodies to truncated VEGF-D and thereof
Term ended
Term ended Dec 21, 2019 · USPTO record
Term endedTerm ended Dec 21, 2019USPTO record
US 7,871,798Mammalian cells that express VEGF-D polypeptides
Formerly held
Term ended
Term ended Mar 24, 2019 · USPTO record
Term endedTerm ended Mar 24, 2019USPTO record
US 7,410,639Vascular endothelial growth factor D(VEGF-D) antibodies and methods of use
Formerly held
Term ended
Term ended Mar 21, 2019 · USPTO record
Term endedTerm ended Mar 21, 2019USPTO record
10 of 59 patents shown.
Pro members see all 59.
Pro members: see all 59 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited